Trump’s FDA nominee grilled on vaccine meeting, agency staffing
Trump's FDA nominee tepidly backs role for vaccine advisers in guarded Senate appearance
Trump's FDA nominee faces Senate questions after agency layoffs and resignations
FDA chief nominee says action to ensure safe school lunches is on his agenda
Dr. Marty Makary is a renowned Johns Hopkins surgeon and President Donald Trump's pick to head the Food and Drug Administration (FDA). He faced senators in a two-hour confirmation hearing Thursday morning taking on topics ranging from medical devices, vapes and food safety to the abortion drug mifepristone.
Read the resignation letter from FDA food director Jim Jones
Jim Jones, director of the Food and Drug Administration’s food division, slammed the “indiscriminate firing” of dozens of his employees and recent rhetoric from Health and Human Services Secretary Robert F. Kennedy Jr. in his resignation letter to acting FDA commissioner Sara Brenner, which The Washington Post has reproduced below.
What to Know About Marty Makary, Trump’s Pick to Lead the FDA
If confirmed, Makary would run one of the nation's leading health agencies, overseeing the regulation of food and drugs.
Trump’s FDA pick made his name by bashing the medical establishment. Soon he may be leading it
Food and Drug Administration nominee Dr. Marty Makary is known for his contrarian views and fiery criticism of traditional medical institutions.
FDA pick may differ from HHS head RFK Jr. in some key areas
Martin Makary, an author and surgeon at Johns Hopkins University, has appeared frequently on Fox News to talk about health issues.
MedPage Today3d
Makary Sails Through Nomination Hearing for FDA Commissioner
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Marty Makary, MD, MPH, President Trump's nominee for FDA commissioner, seems likely to be a lock for the position if ...
Medscape3d
As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
A new federal commission will ‘investigate’ decades-old mental health as well as weight loss drugs, prompting concerns from clinicians and patients. What could the FDA do to restrict or revoke approvals for these drugs?